Roche Holding agreed to acquire U.S. biotech Ignyta for $1.7 billion, following Bayer in buying into a class of experimental cancer drugs that home in on a specific mutation across many types of tumors.
Ignyta investors will get $27 a share in cash, the companies said in a statement Friday. That’s 74% higher than Thursday’s closing price. Both companies’ boards agreed to the deal.
Roche’s purchase comes about five weeks after Bayer signed a $1.55 billion licensing deal for Loxo Oncology’s larotrectinib, an experimental medicine similar to Ignyta’s entrectinib. Roche has said it will focus on small deals like Ignyta to build out its portfolio. The Swiss company, the world’s biggest maker of cancer drugs, is facing a critical transition as its three top-selling medicines lose patent protection.
San Diego-based Ignyta’s entrectinib is being tested in patient trials that, if successful, could be the basis for applications with regulators to sell the drug. Roche said it aims to complete the purchase in the first half of 2018.
Citigroup advised Roche on the deal, while Sidley Austin provided legal advice. Ignyta used bankers from BofA Merrill Lynch and J.P. Morgan Securities with Latham & Watkins as legal counsel.
Roche shares fell 0.1% to 246.50 Swiss francs at 9:10 a.m. in Zurich, valuing the company at 213 billion francs ($215 billion).
Ignyta was founded in 2011 by University of California, San Diego researcher Gary Firestein and Jonathan Lim, the former chief executive officer of Halozyme Therapeutics Inc.
Source: Bloomberg via Fortune
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).